KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.

In a regulatory milestone, the FDA clears AuraWell’s PEMF technology as the first over-the-counter frequency therapy device for at-home recovery. As the at-home wellness and recovery market continues ...

Chicago Capital sold 377,850 shares of PRCT in the fourth quarter; the estimated transaction value was $12.53 million based on quarterly average pricing. Meanwhile, the quarter-end position value ...

Super Bowl champions Bruce Arians and Rob Gronkowski star in a cheeky Super Bowl ad from Novartis designed to encourage men to get screened for prostate cancer with an easy blood test. Arians and ...

Credit: Getty Images This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men. Familial clustering studies ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

The MarketWatch News Department was not involved in the creation of this content. Results of 244-Patient Study to Support Planned FDA Pre-Market Approval (PMA) Application BOSTON and YOKNEAM, Israel, ...

BOSTON and YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- Butterfly Medical, developer of a proprietary non-surgical solution for benign prostatic hyperplasia (BPH), today announced the successful ...

UCHealth Longs Peak Hospital in Longmont, Colo., is using a robot-assisted procedure that incorporates AI to treat benign prostatic hyperplasia, or BPH, a common condition among older men. The ...